在日本的De Novo转移性化敏感前列腺癌中,现实世界的治疗选择和共享决策
Nobuki Furubayashi1, Jiro Tsujita1, Azusa Takayama1
1Department of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Cancer diagnosis & prognosis
|March 4, 2026
概括
在日本,三重疗法越来越多地用于转移性割敏感前列腺癌 (mCSPC). 早期的结果显示PSA下降率很高,年龄影响治疗强度超过疾病负担.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
背景情况:
- 转移性割敏感前列腺癌 (mCSPC) 是一个重大的临床挑战.
- 三重疗法的引入改变了新的mCSPC的治疗范式.
研究的目的:
- 在日本的 de novo mCSPC 患者中描述一线治疗选择.
- 评估不同治疗策略的早期结果,包括三重疗法.
主要方法:
- 在一家日本癌症中心接受治疗的46名 de novo mCSPC患者的回顾性分析.
- 患者被分为单疗法 (ADT 单疗法),双疗法 (ADT + ARSI) 或三疗法 (ADT + docetaxel + darolutamide) 的组.
主要成果:
- 三重疗法显示出高的前列腺特异抗原 (PSA) 衰减率 (100%).
- 发烧性中性质减退 (5.3%),间歇性肺炎 (5.3%) 和外围神经病变 (10.5%) 在三重组中观察到.
- 接受单一治疗的患者比双重和三重组的患者年龄大得多.
结论:
- 日本 de novo mCSPC 的治疗强度主要受患者年龄的影响.
- 三疗法在精选的mCSPC患者中显示出有前途的早期疗效.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...


